Showing 1591-1600 of 5063 results for "".
- San Diego Dermatology Symposium Reschedules to Septemberhttps://practicaldermatology.com/news/san-diego-dermatology-symposium-reschedules-to-september/2460350/San Diego Dermatology Symposium will be held September 11-13, 2020, a shift from its original date. "The safety of our attendees, faculty, and exhibitors is our utmost priority, and we have been closely monitoring guidance from federal, state and local governments, as well as the World Healt
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir
- Dupixent Significantly Improves Severe AD in Childrenhttps://practicaldermatology.com/news/dupixent-significantly-improves-severe-ad-in-children/2460338/Dupixent showed significant improvement in severe atopic dermatitis (AD) for children aged 6 to 11 Years, according to a Phase 3 study. In the trial, Dupixent combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related q
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- Positive Phase 3 Results Reported for Medimetriks and Otsuka's AD Drughttps://practicaldermatology.com/news/positive-phase-3-results-reported-for-medimetriks-and-otsukas-ad-drug-1/2460322/Medimetriks Pharmaceuticals, Inc. and Otsuka Pharmaceuticals Co. Ltd.’s MM36 (difamilast) performed well in two Phase 3 Japanese clinical trials in adult and pediatric atopic dermatitis (AD) patients. Difamilast is a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibit
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- Destiny Pharma and MedPharm Complete Initial Phase of Development Projecthttps://practicaldermatology.com/news/destiny-pharma-and-medpharm-complete-initial-phase-of-development-project/2460318/Destiny Pharma and MedPharm have completed the initial phase of their project to develop new topical formulations of Destiny’s novel XF‐platform drugs. Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations w
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre
- HHS OCR: New HIPAA Guidance to Support e-Consultshttps://practicaldermatology.com/news/hhs-ocr-new-hipaa-guidance-to-support-e-consults/2460309/Practices that haven’t contracted with a telehealth platform may still be able to provide virtual consults using standard telecommunications technologies throughout the COVID-19 pandemic. The Office for Civil Rights (OCR) at the Department of Health and Human Services (HHS)